Drug Trial Radar · NCT07228403
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
28
Actual
Start
Dec 11, 2025
Primary completion
Sep 18, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials. Participants currently on these trials will be able to continue their glepaglutide treatment by enrolling in this EASE SBS 6 extension trial. The trial includes a 24-month treatment period, followed by a 4-week safety follow-up period. Participants will attend trial visits, where they may undergo heart tests (electrocardiogram (ECG)), vital sign checks, colonoscopies, blood and urine tests, and physical exams.
Conditions
- Short Bowel Syndrome (SBS)
Interventions
Glepaglutide 10 mgDrug
Administered twice weekly by subcutaneous injection for a maximum of 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment emergent adverse events (TEAEs)Time frame: From baseline to the safety follow-up visit (A maximum of 25 months)
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
Mayo Clinic - PPDS
Rochester, Minnesota
Lied Transplant Center at Nebraska Medical Center
Omaha, Nebraska
Cleveland Clinic-9500 Euclid Ave
Cleveland, Ohio
Vanderbilt University Medical Center-Tennesse-1211 21st Ave S
Nashville, Tennessee
UZ Leuven - PPDS
Leuven, Belgium
LHSC - University Hospital
London, Ontario, Canada
AP-HP - Hôpital Beaujon
Clichy, Hauts-de-Seine, France
Asklepios Klinik St. Georg
Hamburg, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany
Universitätsmedizin Rostock
Rostock, Mecklenburg-Vorpommern, Germany
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, Germany
Wojewódzki Szpital Specjalistycznyo im. M. Pirogowa w Lodzi
Lodz, Poland
Szpital Skawina sp. z o.o. im. Stanley Dudricka
Skawina, Lesser Poland Voivodeship, Poland
Samodzielny Publiczny Szpitala Kliniczny im. Prof. Witolda Orlowskiego CMKP
Warsaw, Masovian Voivodeship, Poland
St Mark's Hospital (Central Middlesex Hospital)
Ealing, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.